Literature DB >> 22072681

Inhibition of the Ca²⁺-dependent K⁺ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury.

Delphine Bouhy1, Nader Ghasemlou, Starlee Lively, Adriana Redensek, Khizr I Rathore, Lyanne C Schlichter, Samuel David.   

Abstract

Spinal cord injury (SCI) triggers inflammatory responses that involve neutrophils, macrophages/microglia and astrocytes and molecules that potentially cause secondary tissue damage and functional impairment. Here, we assessed the contribution of the calcium-dependent K⁺ channel KCNN4 (KCa3.1, IK1, SK4) to secondary damage after moderate contusion lesions in the lower thoracic spinal cord of adult mice. Changes in KCNN4 mRNA levels (RT-PCR), KCa3.1 protein expression (Western blots), and cellular expression (immunofluorescence) in the mouse spinal cord were monitored between 1 and 28 d after SCI. KCNN4 mRNA and KCa3.1 protein rapidly increased after SCI; double labeling identified astrocytes as the main cellular source accounting for this upregulation. Locomotor function after SCI, evaluated for 28 d in an open-field test using the Basso Mouse Scale, was improved in a dose-dependent manner by treating mice with a selective inhibitor of KCa3.1 channels, TRAM-34 (triarylmethane-34). Improved locomotor function was accompanied by reduced tissue loss at 28 d and increased neuron and axon sparing. The rescue of tissue by TRAM-34 treatment was preceded by reduced expression of the proinflammatory mediators, tumor necrosis factor-α and interleukin-1β in spinal cord tissue at 12 h after injury, and reduced expression of inducible nitric oxide synthase at 7 d after SCI. In astrocytes in vitro, TRAM-34 inhibited Ca²⁺ signaling in response to metabotropic purinergic receptor stimulation. These results suggest that blocking the KCa3.1 channel could be a potential therapeutic approach for treating secondary damage after spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072681      PMCID: PMC6633238          DOI: 10.1523/JNEUROSCI.0047-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  39 in total

1.  Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.

Authors:  Zhihua Yu; Panpan Yu; Hongzhuan Chen; Herbert M Geller
Journal:  J Neurochem       Date:  2014-03-27       Impact factor: 5.372

2.  Neuronal expression of the intermediate conductance calcium-activated potassium channel KCa3.1 in the mammalian central nervous system.

Authors:  Ray W Turner; Mirna Kruskic; Michelle Teves; Teresa Scheidl-Yee; Shahid Hameed; Gerald W Zamponi
Journal:  Pflugers Arch       Date:  2014-05-06       Impact factor: 3.657

3.  Involvement of TRPM4 in detrusor overactivity following spinal cord transection in mice.

Authors:  F Aura Kullmann; Jonathan M Beckel; Bronagh McDonnell; Christian Gauthier; Andrew M Lynn; Amanda Wolf-Johnston; Anthony Kanai; Irina V Zabbarova; Youko Ikeda; William C de Groat; Lori A Birder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-27       Impact factor: 3.000

4.  Ca2+-activated K+ channels modulate microglia affecting motor neuron survival in hSOD1G93A mice.

Authors:  Germana Cocozza; Maria Amalia di Castro; Laura Carbonari; Alfonso Grimaldi; Fabrizio Antonangeli; Stefano Garofalo; Alessandra Porzia; Michele Madonna; Fabrizio Mainiero; Angela Santoni; Francesca Grassi; Heike Wulff; Giuseppina D'Alessandro; Cristina Limatola
Journal:  Brain Behav Immun       Date:  2018-07-03       Impact factor: 7.217

5.  Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole.

Authors:  B-S Liu; R Ferreira; S Lively; L C Schlichter
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-19       Impact factor: 4.147

Review 6.  Regulation of neurovascular coupling in autoimmunity to water and ion channels.

Authors:  Peter Jukkola; Chen Gu
Journal:  Autoimmun Rev       Date:  2014-11-22       Impact factor: 9.754

7.  KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Authors:  Mengni Yi; Panpan Yu; Qin Lu; Herbert M Geller; Zhihua Yu; Hongzhuan Chen
Journal:  Mol Cell Neurosci       Date:  2016-08-24       Impact factor: 4.314

Review 8.  Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?

Authors:  Corina M Balut; Kirk L Hamilton; Daniel C Devor
Journal:  ChemMedChem       Date:  2012-08-07       Impact factor: 3.466

Review 9.  Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.

Authors:  Heike Wulff; Ralf Köhler
Journal:  J Cardiovasc Pharmacol       Date:  2013-02       Impact factor: 3.105

Review 10.  Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.

Authors:  Roland G W Staal; Jonathan R Weinstein; Megan Nattini; Manuel Cajina; Gamini Chandresana; Thomas Möller
Journal:  Neurochem Res       Date:  2017-03-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.